U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT07585097) titled 'A Study to Observe the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment' on May 06.
Brief Summary: This study will collect information from patients with ALGS who are using odevixibat in their daily lives. Odevixibat is a medication that helps patients with ALGS, a rare disease that affects the liver and causes itching.
The main aim of this study is to observe the long-term, everyday safety of the drug odevixibat in patients with ALGS who are receiving ongoing treatment.
Study Start Date: Sept. 30, 2026
Study Type: OBSERVATIONAL
Condition:
Alagille Syndrome
Recruitment...